Join the Oncology Voice Network. Join for Free
The Gamification of MSL Metrics
Gamifying MSL Metrics Medical Affairs Innovation MSL Performance Evaluation High-Impact Activities MSL Success Strategies

The Gamification of MSL Metrics


Share This Article


Summary

In this episode, Bart Brown joins Tom Caravela to explore the concept of gamifying MSL metrics. Bart shares his innovative point system designed to evaluate MSL performance beyond traditional metrics. They delve into the challenges of current evaluation methods and discuss how this new system emphasizes high-impact activities and diverse success strategies. Bart provides insights on implementing these strategies and addresses potential downsides. The conversation highlights the importance of showcasing value in Medical Affairs. The episode wraps up with a call for listener feedback and suggestions for future topics.

My guest this week is Bart Brown, Medical Affairs Leader who shares his interesting concept on how to gamify MSL metrics and KPIs.

Bart shares….

👉 How are MSLs currently evaluated and what is the standard
👉 A unique way to “gamify” MSL metrics and KPIs
👉 How this unique system can be implemented and why
👉 What the benefits would be to this system
👉 What advice he has for MSL success in 2024

Click for Source
Gamifying MSL Metrics, Medical Affairs Innovation, MSL Performance Evaluation, High-Impact Activities, MSL Success Strategies

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Explore OVN